Navigation Links
FDA Accepts Ranexa(R) sNDA and NDA for Filing
Date:11/19/2007

PALO ALTO, Calif., Nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its supplemental new drug application (sNDA) and new drug application (NDA) for Ranexa(R) (ranolazine extended- release tablets) have both been accepted for filing. The Prescription Drug User Fee Act (PDUFA) action date for both applications is July 27, 2008.

The sNDA seeks an expansion to the approved product labeling for Ranexa(R) (ranolazine extended-release tablets) to include a first line angina indication and a significant reduction in cautionary language. The sNDA is being reviewed by the FDA Division of Cardiovascular Renal Products.

After receiving this sNDA submission from CV Therapeutics, the FDA initiated, and has now accepted for filing, a separate NDA on behalf of the Company to provide a clinical review of a potential labeling change to add reduction of hemoglobin A1c (HbA1c) in coronary artery disease patients with diabetes. This NDA is being reviewed by the FDA Division of Metabolism and Endocrinology Products.

"With the Ranexa sNDA and NDA now accepted for filing, the NDA under review for regadenoson and our marketing authorization application for ranolazine under review in Europe, we are very excited to have several major applications in process and are looking forward to multiple potential approvals in 2008," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

In accordance with a special protocol assessment agreement between the FDA and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
4. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
10. Prana Announces Filing of Annual Report
11. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ATTLE,Nov.24/PRNewswire-FirstCall/--CellTherapeuti...ntatthe21stAnnualPiperJaffrayHealthCareConference....rkPalaceHotel. ,, CTIwillpresentonTuesday,Decem...eaudiowebcastofCTI,spresentationwillbeavailableat ...forreplayafterwards. , ,PiperJaffrayHealthCareCon...
(Date:11/23/2009)...N, Ill. You can think of it as origami very high... Illinois have developed a technique for fabricati...tructures from thin films by coupling photolithogr...y interactions. , The films, only a few microns t...sible with thicker pieces of the same material. ,...
(Date:11/23/2009)... consists of a two-dimensional carbon layer in whi...ttice, resembling a honeycomb. Carbon nanotubes ar... graphene sheets form graphite. Graphene boasts so...ear-resistant, an excellent thermal conductor, and...ess and ductility. In addition, graphene is imperm...
(Date:11/23/2009)...SSISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioSci...uctdevelopmentcompanythatidentifiesandadvancesadiv...riousstagesofdevelopment,todayreportedthatCytopia(...luatingCYT387,apotent,orally-administeredJAK1/JAK2...chester,Minnesota.AproposaltomergeCytopiaintoYMhas...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...-dose cohorts plus data from subsequent higher-dos..., Calif., March 18 InterMune, Inc. (Nasdaq: ITM...ical study of ITMN-191 (R7227) in combination with...ferred to as the INFORM-1 study, has been accepted... at the 44th Annual Meeting of the European Associ...
.... Wright, Co-Chair of the Alliance for Biosecurity...ied today before the House Labor, Health and Human...ee on the critical importance of developing drugs,... to protect Americans from bioterrorism and other ... countermeasures for many of the chemical, biologi...
...Marin Pharmaceutical Inc. (Nasdaq: BMRN ) announ...authorization (CTA) for BMN 110 or N-acetylgalacto...ment of the lysosomal storage disorder Mucopolysac...me, has been accepted by the United Kingdom Medici...A). BioMarin expects to initiate a Phase 1/2 clini...
Other Biology Technology:INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 2INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 3INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 4Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:11/24/2009)...that may help gut bacteria bind to the gastrointes...c producers to identify strains that are likely to... to interact with cells lining the gut to have a b...n the gut they are more likely to stick around lon...e Juge from the Institute of Food Research. IFR i...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009)... of debate. A high-profile study a few years ago s...carbon from trees and leaves, evidence for a very ...systems. , But new research from the University ... Algae provide a much richer diet for fish and oth...his week in the Proceedings of the National Acade...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 1The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 2The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 3Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 1Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 2
...ilian personnel from the U.S. Armed Forces, as wel...aw enforcement and other first-responder personnel...dia have been encouraged to register and attend th...PED VII). The event will be held at Stafford Regio...uring May 19-21. , , The demonstration, which is ...
..., University of Alabama at Birmingham professor of...Prize for Outstanding Innovation in Life Sciences....salutes Weaver,s achievements in advancing underst...ough T cell research. , According to Weaver, our...and cancer, but when T cells overreact and turn on...
...ng diverse forests for multiple uses is important ...dy conducted in southwestern Oregon provides fores...en managing land for a variety objectives that may...te level of wood production with some wildlife hab...s cover and forage for a wider variety of wildlife...
Other Biology News:Demonstration Features Commercial Technology for Combating Terrorism 2UAB professor receives HudsonAlpha Innovation Prize 2Managing Douglas-fir forests for diversity 2
PARP Cleavage Immunoblotting Assay Kit from Upstate
...o-Sequencing is designed to aid sequence analysis ...ning sites (MCS) of M13 phage vectors (mp18/19) or...). The kit is used to create nested unidirectional...y moving the primer binding site on the vector clo...
MaxArray Rat Brain Tissue Slides from Invitrogen
...ion Kit, 100 reactions. Prepare circular DNA templ...ram quantities of template DNA from picogram amoun... for cycle sequencing without purification.Amplify...es, plaques, or purified circular (plasmid or M13)...
Biology Products: